MX2022003365A - Anticuerpos de un solo dominio dirigidos contra lilrb2. - Google Patents

Anticuerpos de un solo dominio dirigidos contra lilrb2.

Info

Publication number
MX2022003365A
MX2022003365A MX2022003365A MX2022003365A MX2022003365A MX 2022003365 A MX2022003365 A MX 2022003365A MX 2022003365 A MX2022003365 A MX 2022003365A MX 2022003365 A MX2022003365 A MX 2022003365A MX 2022003365 A MX2022003365 A MX 2022003365A
Authority
MX
Mexico
Prior art keywords
directed against
domain antibodies
antibodies directed
lilrb2
against lilrb2
Prior art date
Application number
MX2022003365A
Other languages
English (en)
Inventor
Julien Caumartin
Maria Loustau
Lise Hunault
Pierre Langlade-Demoyen
Original Assignee
Invectys SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invectys SAS filed Critical Invectys SAS
Publication of MX2022003365A publication Critical patent/MX2022003365A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)

Abstract

La presente invención se refiere a anticuerpos de un solo dominio (sdAbs) dirigidos contra el miembro 2 de la subfamilia B del receptor de tipo inmunoglobulina leucocitaria (LILRB2), composiciones farmacéuticas que los comprenden y sus usos en diagnóstico y en terapia.
MX2022003365A 2019-09-20 2020-09-18 Anticuerpos de un solo dominio dirigidos contra lilrb2. MX2022003365A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306148 2019-09-20
PCT/EP2020/076198 WO2021053199A1 (en) 2019-09-20 2020-09-18 Single-domain antibodies directed against lilrb2

Publications (1)

Publication Number Publication Date
MX2022003365A true MX2022003365A (es) 2022-08-22

Family

ID=68654426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003365A MX2022003365A (es) 2019-09-20 2020-09-18 Anticuerpos de un solo dominio dirigidos contra lilrb2.

Country Status (11)

Country Link
US (1) US20230235050A1 (es)
EP (1) EP4031572A1 (es)
JP (1) JP2022548764A (es)
KR (1) KR20220128332A (es)
CN (1) CN115066435A (es)
AU (1) AU2020351274A1 (es)
BR (1) BR112022004534A2 (es)
CA (1) CA3154450A1 (es)
IL (1) IL291506A (es)
MX (1) MX2022003365A (es)
WO (1) WO2021053199A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116333127A (zh) * 2022-06-28 2023-06-27 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN114805568B (zh) * 2022-06-28 2022-09-02 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
WO2024022462A1 (zh) * 2022-07-29 2024-02-01 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
WO2024041315A1 (en) * 2022-08-22 2024-02-29 Antengene (Hangzhou) Biologics Co., Ltd. Novel anti-lilrb2 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CA2687633A1 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
WO2016111947A2 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EP3728318A2 (en) * 2017-12-22 2020-10-28 Jounce Therapeutics, Inc. Antibodies for lilrb2
EP3740224A4 (en) * 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES

Also Published As

Publication number Publication date
EP4031572A1 (en) 2022-07-27
US20230235050A1 (en) 2023-07-27
CA3154450A1 (en) 2021-03-25
IL291506A (en) 2022-05-01
BR112022004534A2 (pt) 2022-06-07
CN115066435A (zh) 2022-09-16
AU2020351274A1 (en) 2022-05-05
KR20220128332A (ko) 2022-09-20
WO2021053199A1 (en) 2021-03-25
JP2022548764A (ja) 2022-11-21

Similar Documents

Publication Publication Date Title
MX2022003365A (es) Anticuerpos de un solo dominio dirigidos contra lilrb2.
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
PH12018501419A1 (en) Pharmaceutical composition comprising bispecific antibody constructs
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
MX2019003544A (es) Composiciones que comprenden un ligando de union al receptor cannabinoide.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
WO2018109174A3 (en) Il-11 antibodies
MX2021008592A (es) Composiciones de trem y usos de las mismas.
WO2018006074A3 (en) Compounds and methods for modulating rna function
MX2017013196A (es) Bioconjugados y usos de los mismos.
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
WO2017214462A3 (en) Anti-cd98 antibodies and antibody drug conjugates
EP4245775A3 (en) Multi-specific binding conjugate, related pharmaceutical compositions and use
PH12020550890A1 (en) Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
MX2020003093A (es) Anticuerpos anti-cd19 novedosos.
MX2019001121A (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion.
MY194084A (en) Interferon beta antibodies and uses thereof
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2020005364A (es) Anticuerpos anti-ox40 y usos de los mismos.
MX2020013170A (es) Composicion agricola.
WO2015145449A3 (en) T-cell receptor cdr3 peptides and antibodies
MX2009003300A (es) Vectores de rhinovirus recombinantes.
PH12019502694A1 (en) Anti-trkb antibodies